sanofi-aventis

1 Onslow Street, Guildford, Surrey, GU1 4YS, UK
Telephone: +44 (0)1483 505 515
Fax: +44 (0)1483 535 432
Medical Information e-mail: uk-medicalinformation@sanofi-aventis.com


Summary of Product Characteristics last updated on the eMC: 03/08/2007
SPC Anthisan Cream


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

AnthisanTM Cream.


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Mepyramine maleate BP 2.0% w/w.


Go to top of the page
3. PHARMACEUTICAL FORM

Cream.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

Symptomatic relief in insect stings and bites and nettle rash.

Route of Administration: Topical.


Go to top of the page
4.2 Posology and method of administration

Adults, elderly and children. Anthisan Cream should be applied directly to the affected parts two or three times a day for up to three days. Early application is essential to obtain the optimum response.


Go to top of the page
4.3 Contraindications

Anthisan Cream should not be used in eczematous conditions or on extensively broken skin surfaces.


Go to top of the page
4.4 Special warnings and precautions for use

Repeated application of Anthisan Cream for periods longer than a few days is not recommended and treatment should be discontinued immediately if skin sensitisation occurs.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

No significant interactions described.


Go to top of the page
4.6 Pregnancy and lactation

There is no evidence of the safety of mepyramine maleate in human pregnancy, but it has been widely used for many years without apparent ill consequence. Absorption of a significant amount after topical application is unlikely in the prescribed method of use, nevertheless, Anthisan Cream should not be used during pregnancy or lactation, unless considered essential.


Go to top of the page
4.7 Effects on ability to drive and use machines

May theoretically be extensively absorbed through the skin when applied over large areas and cause somnolence and mild disorientation.


Go to top of the page
4.8 Undesirable effects

Skin sensitisation has been reported on rare occasions.


Go to top of the page
4.9 Overdose

A 25g tube of Anthisan Cream contains 500mg mepyramine maleate. If accidentally ingested this dose would constitute a dangerous overdose in young children.

The chief symptom of overdosage is unconsciousness and there may be convulsions in the intervening periods. The stomach should be washed out. Stimuli liable to provoke convulsions should be avoided, but if this complication should occur, parenteral Diazepam should be given; sedatives which are liable to increase respiratory depression should be avoided. Other measures such as artificial respiration and oxygen may also be required and an antibiotic can be given as a prophylactic against pneumonia.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Mepyramine maleate is an antihistamine with antipruritic and local analgesic actions.


Go to top of the page
5.2 Pharmacokinetic properties

No pharmacokinetic data available by any route of administration.


Go to top of the page
5.3 Preclinical safety data

There are no findings of relevance to the prescriber, additional to those already included elsewhere in the SPC.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Ceto-stearyl alcohol BP, Polyethylene glycol 600 monostearate, Castor oil BP, Methyl hydroxybenzoate BP, Foin coupe, Silicone antifoam, Purified water BP.


Go to top of the page
6.2 Incompatibilities

Not applicable.


Go to top of the page
6.3 Shelf life

36 months.


Go to top of the page
6.4 Special precautions for storage

Do not store above 30oC.


Go to top of the page
6.5 Nature and contents of container

Collapsible aluminium tube with extended nozzle and polythene cap containing 25g cream.


Go to top of the page
6.6 Special precautions for disposal and other handling

None stated.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Sanofi-aventis

One Onslow Street

Guildford

Surrey, GU1 4YS, UK


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 04425/0274


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

4th April 2002


Go to top of the page
10. DATE OF REVISION OF THE TEXT

November 2006


Go to top of the page
11 LEGAL CLASSIFICATION

P



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/9114/SPC/


Active Ingredients/Generics

 
   mepyramine maleate